UPDATE 2-Mylan defends King deal amid investor concerns
38488
Generic drug maker Mylan Laboratories Inc. reaffirmed on Wednesday its planned $3.37 billion purchase of King Pharmaceuticals Inc.
33756
Schering-Plough Corp and Merck & Co are defending their shared cholesterol treatments, Vytorin and Zetia, in advertisements after a failed study generated negative publicity.
639218
NEW YORK, November 22  - Mylan Labsâ (MYL.NYS) board of directors rejected investor Carl Icahnâs takeover bid today, terming his offer letter as a self serving publicity stunt, while reiterating the companyâs intention to proceed
654843
Financier Carl Icahn offered Friday to purchase all outstanding shares of Mylan Laboratories Inc. for $20 per share, which would value the company at approximately $5.4 billion, according to The Wall Street Journal.
82314
As criticism mounted yesterday over Banknorth Group's pending deal with a Canadian bank, chief executive William J. Ryan defended his decision to sell a majority stake in New England's largest independent bank, saying it is in the shareholders' best interest.
282450
Mylan Laboratories Inc., the biggest US maker of generic drugs, received a $20-a-share bid from Carl Icahn, the company&#39;s largest investor and a critic of Mylan&#39;s plan to buy King Pharmaceuticals Inc.
561858
-- Mylan Laboratories  Inc.MYL.N on Wednesday said it is unlikely to complete its  $3.37 billion acquisition of King Pharmaceuticals Inc.KG.N at  the current price because of King's need to restate earnings.
439046
Unwritten assurances from Enron Corp. to keep trying to sell Merrill Lynch &amp; Co.&#39;s $7 million interest in three power-generating barges wasn&#39;ta &quot;legal impediment&quot; to making that investment, an in-house lawyer for the brokerage testified Monday.
260004
Mylan Laboratories Inc. on Wednesday said it was unlikely to complete its &#36;3.80 billion acquisition of King Pharmaceuticals Inc. at the current price because of King's need to restate earnings.
292602
Drugmaker Mylan Laboratories Inc.  posted a quarterly loss on Thursday on charges related to an acquisition, but reported adjusted profit that beat its previous forecast helped by sales of generic drugs for pain and bladder control.
131989
A Mylan Laboratories shareholder is suing the Canonsburg generic drug maker and its directors, saying they have failed their fiduciary obligations by not considering billionaire investor Carl Icahn&#39;s $20 per share offer for the company.
251456
The war of words between Mylan Laboratories Inc. and the company&#39;s largest shareholder over Mylan&#39;s $4 billion deal to acquire King Pharmaceuticals Inc.
755767
Mylan Laboratories Inc.'s MYL.N board  on Monday rebuffed financier Carl Icahn's bid to buy the  company, and said it remains committed to its $3.37 billion  purchase of brand-name drug-maker King Pharmaceuticals Inc.  KG.N.
94977
Mylan Laboratories Inc.&#39;s board Monday shunned an overture by financier Carl Icahn and said the company intends to remain independent while pursuing its proposed acquisition of King Pharmaceuticals, which Icahn opposes.
357770
Veteran financier Carl Icahn said he and a group of investors are willing to buy Mylan Laboratories Inc. for $20 per share, according to a Friday filing with the Securities and Exchange Commission.
272040
Billionaire investor Carl Icahn and a group of investors are opposing yet another corporate takeover. The investors, led by Icahn, have accumulated a 7 percent stake in Mylan Laboratories Inc.
189520
Shares of Mylan Laboratories Inc., the largest US maker of generic drugs, surged Thursday after the company said investor Carl Icahn was given the green light by regulators to buy up to $500 million of the company&#39;s stock.